Biology subjects

Kuosmanen, J.

Publications and source records attributed to Kuosmanen, J..

4 recordsLinked to original sources

bioRxiv2024

An ingestible, battery-free, tissue-adhering robotic interface for non-invasive and chronic electrostimulation of the gut

Ingestible electronics have the capacity to transform our ability to effectively diagnose and potentially treat a broad set of conditions. Current applications could be significantly enhanced by addressing poor electrode-tissue contact, lack of navigation, short dwell time, and limited battery life. Here we report the development of an ingestible, battery-free, and tissue-adhering robotic interface (IngRI) for non-invasive and chronic electrostimulation of the gut, which addresses challenges associated with contact, navigation, retention, and powering (C-N-R-P) faced by existing ingestibles. We show that near-field inductive coupling operating near 13.56 MHz was sufficient to power and modulate the IngRI to deliver therapeutically relevant electrostimulation, which can be further enhanced by a bio-inspired, hydrogel-enabled adhesive interface. In swine models, we demonstrated the electrical interaction of IngRI with the gastric mucosa by recording conductive signaling from the subcutaneous space. We further observed changes in plasma ghrelin levels, the "hunger hormone," while IngRI was activated in vivo, demonstrating its clinical potential in regulating appetite and treating other endocrine conditions. The results of this study suggest that concepts inspired by soft and wireless skin-interfacing electronic devices can be applied to ingestible electronics with potential clinical applications for evaluating and treating gastrointestinal conditions.

bioengineering↗

bioRxiv2023

Electroadhesive hydrogel interface for prolonged mucosal theranostics

Establishing a robust and intimate mucosal interface that allows medical devices to remain within lumen-confined organs for extended periods has valuable applications, particularly for gastrointestinal (GI) theranostics. Here, we report the development of e-GLUE, an electroadhesive hydrogel interface for robust and prolonged mucosal retention following electrical activation. Notably, this novel mucosal adhesion mechanism can increase the adhesion energy of hydrogels on the mucosa by up to 30-fold and enable in vivo GI retention of e-GLUE devices for up to 30 days. Strong mucosal adhesion occurs within one minute of electrical activation, despite the presence of luminal fluid, mucus exposure, and organ motility, thereby ensuring compatibility with complex in vivo environments. In swine studies, we demonstrate the utility of e-GLUE for mucosal hemostasis, sustained local delivery of therapeutics, and intimate biosensing in the GI tract. This system can enable improved treatments for various health conditions, including gastrointestinal bleeding, inflammatory bowel disease, and diagnostic applications in the GI tract and beyond.

bioengineering↗

bioRxiv2022

Ingestible capsule for detecting labile inflammatory biomarkers in situ

Transient molecules in the gastrointestinal (GI) tract, such as nitric oxide and hydrogen sulfide, are key signals and mediators of inflammatory bowel disease (IBD). Because these molecules are extremely short-lived in the body, they are difficult to detect. To track these reactive molecules in the GI tract, we have developed a miniaturized device that integrates genetically-engineered probiotic biosensors with a custom-designed photodetector and readout chip. Leveraging the molecular specificity of living sensors, we genetically encoded bacteria to respond to IBD-associated molecules by luminescing. Low-power electronic readout circuits (nanowatt power) integrated into the device convert the light from just 1 L of bacterial culture into a wireless signal. We demonstrate biosensor monitoring in the GI tract of small and large animal models and integration of all components into a sub-1.4 cm3 ingestible form factor capable of supporting wireless communication. The wireless detection of short-lived, disease-associated molecules could support earlier diagnosis of disease than is currently possible, more accurate tracking of disease progression, and more timely communication between patient and their care team supporting remote personalized care.

synthetic biology↗

bioRxiv2020

C57BL6 mouse substrains demonstrate differences in susceptibility to the demyelinating effects of Cuprizone toxin

Advances in our understanding of cellular functions and phenotypes in the brain rely on technically robust experimental in vivo models with face validity towards human disease. The cuprizone toxin-induced demyelination model is widely used to investigate pathophysiological mechanisms of demyelinating and remyelinating phases of multiple sclerosis. The C57BL6 mouse is a common inbred strain used as the genetic background for genetically engineered and congenic mice. Substrains of C57BL6 mice sourced from distinct vendors are often treated as equivalent in research studies. Here, we demonstrated that an alternative dosing approach via oral gavage with a well-tolerated, lower dose of cuprizone resulted in significant differences in C57BL/6NTac (Taconic) over C57BL/6J (Jax) mice. With consistent dosing of cuprizone for 5 weeks, body weights were significantly affected in C57BL/6NTac versus C57BL/6J mice. DT-MRI showed significant demyelination in white matter regions in the C57BL/6NTac mice. Concomitantly, histology analysis illustrated increased microgliosis and proliferation in C57BL/6NTac compared with C57BL/6J mice. These observations suggest that the C57BL/6NTac substrain of C57BL6 mice is more vulnerable to cuprizone challenge. Genetic factors along with breeder source appear to influence susceptibility to cuprizone toxin. Thus, the awareness of the limitations of in vivo models in addition to informed decision making on the appropriate background substrain can greatly improve sensitivity and reproducibility of results and use for evaluating investigational therapeutics.

neuroscience↗